NCT01173120View on ClinicalTrials.gov

Methotrexate - Inadequate Response Device Sub-Study

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

July 31, 2010

Conditions
Rheumatoid Arthritis (RA)
Interventions
DEVICE

Abatacept combination product (ACP)

Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY